DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins

被引：25

作者：

Wlazlo, AP ^{[1
]}

Deng, HY ^{[1
]}

Giles-Davis, W ^{[1
]}

Ertl, HCJ ^{[1
]}

机构：

[1] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA

来源：

CANCER GENE THERAPY | 2004年 / 11卷 / 06期

基金：

美国国家卫生研究院;

关键词：

DNA; vaccine; papillomavirus; cancer; E6; E7;

D O I：

10.1038/sj.cgt.7700723

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

DNA vaccines expressing the E6 or E7 oncoproteins of human papilloma virus type 16 (HPV-16) in either their wild-type form or fused to sequences that affect intracellular trafficking were tested for induction of protective immunity against tumor cell challenge in two models based on BALB/c and C57Bl/6 mice. The DNA vaccines to E7 gave uniformly disappointing results, while the DNA vaccine that expressed E6 linked to a viral leader sequence protected BALB/c mice against tumor cell challenge given before or after vaccination. The efficacy of this vaccine could be enhanced by a DNA vector prime/viral vector boost regimen. In contrast, priming of mice with the DNA vaccines to E7 reduced the efficacy of a viral vector expressing the same antigen.

引用

页码：457 / 464

页数：8

共 34 条

[1] An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53
Blaszczyk-Thurin, M
O, I
Ertl, HCJ
[J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2002, 56 (04) : 361 - 375
[2] A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
Borysiewicz, LK
Fiander, A
Nimako, M
Man, S
Wilkinson, GWG
Westmoreland, D
Evans, AS
Adams, M
Stacey, SN
Boursnell, MEG
Rutherford, E
Hickling, JK
Inglis, SC
[J]. LANCET, 1996, 347 (9014) : 1523 - 1527
[3] Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7
Daemen, T
Pries, F
Bungener, L
Kraak, M
Regts, J
Wilschut, J
[J]. GENE THERAPY, 2000, 7 (21) : 1859 - 1866
[4] A modified DNA vaccine to p53 induces protective immunity to challenge with a chemically induced sarcoma cell line
Deng, HY
Kowalczyk, D
O, I
Blaszczyk-Thurin, M
Xiang, ZQ
Giles-Davis, W
Ertl, HCJ
[J]. CELLULAR IMMUNOLOGY, 2002, 215 (01) : 20 - 31
[5] VACCINATION WITH CYTOTOXIC T-LYMPHOCYTE EPITOPE-CONTAINING PEPTIDE PROTECTS AGAINST A TUMOR-INDUCED BY HUMAN PAPILLOMAVIRUS TYPE-16-TRANSFORMED CELLS
FELTKAMP, MCW
SMITS, HL
VIERBOOM, MPM
MINNAAR, RP
DEJONGH, BM
DRIJFHOUT, JW
TERSCHEGGET, J
MELIEF, CJM
KAST, WM
[J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (09) : 2242 - 2249
[6] RABIES VIRUS NUCLEOPROTEIN EXPRESSED IN AND PURIFIED FROM INSECT CELLS IS EFFICACIOUS AS A VACCINE
FU, ZF
DIETZSCHOLD, B
SCHUMACHER, CL
WUNNER, WH
ERTL, HCJ
KOPROWSKI, H
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (05) : 2001 - 2005
[7] Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16
Gunn, GR
Zubair, A
Peters, C
Pan, ZK
Wu, TC
Paterson, Y
[J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (11) : 6471 - 6479
[8] Viral recombinant vaccines to the E6 and E7 antigens of HPV-16
He, Z
Wlazlo, AP
Kowalczyk, DW
Cheng, J
Xiang, ZQ
Giles-Davis, W
Ertl, HCJ
[J]. VIROLOGY, 2000, 270 (01) : 146 - 161
[9] Insug O, 2003, Cancer Gene Therapy, V10, P678
[10] Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors
Ji, HX
Wang, TL
Chen, CH
Pai, SI
Hung, CF
Lin, KY
Kurman, RJ
Pardoll, DM
Wu, TC
[J]. HUMAN GENE THERAPY, 1999, 10 (17) : 2727 - 2740

← 1 2 3 4 →